Cargando…
Treatment of Cardiac Fibrosis with Extracellular Vesicles: What Is Missing for Clinical Translation?
Heart failure is the leading cause of morbidity and mortality and currently affects more than 60 million people worldwide. A key feature in the pathogenesis of almost all forms of heart failure is cardiac fibrosis, which is characterized by excessive accumulation of extracellular matrix components i...
Autores principales: | Neuber, Sebastian, Ermer, Miriam R., Emmert, Maximilian Y., Nazari-Shafti, Timo Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342089/ https://www.ncbi.nlm.nih.gov/pubmed/37445658 http://dx.doi.org/10.3390/ijms241310480 |
Ejemplares similares
-
Hopes and Hurdles of Employing Mesenchymal Stromal Cells in the Treatment of Cardiac Fibrosis
por: Neuber, Sebastian, et al.
Publicado: (2021) -
Human mesenchymal stromal cells and derived extracellular vesicles: Translational strategies to increase their proangiogenic potential for the treatment of cardiovascular disease
por: Nazari‐Shafti, Timo Z., et al.
Publicado: (2020) -
MiRNA Profiles of Extracellular Vesicles Secreted by Mesenchymal Stromal Cells—Can They Predict Potential Off-Target Effects?
por: Nazari-Shafti, Timo Z., et al.
Publicado: (2020) -
The path to a hemocompatible cardiovascular implant: Advances and challenges of current endothelialization strategies
por: Exarchos, Vasileios, et al.
Publicado: (2022) -
MicroRNA Mediated Cardioprotection – Is There a Path to Clinical Translation?
por: Nazari-Shafti, Timo Z., et al.
Publicado: (2020)